OCREVUS sous-cutané sol inj 920 mg/23 ml flac
7680689880013
CH-68988
L04AG08
01.99.0.
Reimbursement limitations:
OCREVUS.01
Pour le traitement des patients adultes atteints de formes actives de sclérose en plaques (SEP) …
1 / 3
google
Details
- Product number
- 6898801
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- ocrelizumabum 920 mg, hyaluronidasum humanum ADNr, trehalosum dihydricum, acidum aceticum glaciale, methioninum, polysorbatum 20, natrii acetas trihydricus, aqua ad iniectabile ad solutionem pro 23 ml corresp. natrium 8.4 mg.
Articles (1)
Ocrevus subkutan 920 mg/23 ml, Injektionslösung
Injektionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
920.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
8.4 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 9813.60
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2025
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 68988
- Drug name
- Ocrevus subkutan, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- L04AG08
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 15/11/2024
- Authorization expiration date
- 14/11/2029
- IT number
- 01.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- OCREVUS sous-cutané sol inj 920 mg/23 ml flac
- Description (DE)
- OCREVUS subkutan Inj Lös 920 mg/23 ml Durchstf
- Market launch
- 15/11/2024
- Narcotic (BTM)
- No